Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States

Dzintars Gotham, Lorenzo Moja, Maarten van der Heijden, Sarah Paulin, Ingrid Smith and Peter Beyer

Health Policy, 2021, vol. 125, issue 3, 296-306

Abstract: The pipeline of new antibacterials remains limited. Reasons include low research investments, limited commercial prospects, and scientific challenges. To complement existing initiatives such as research grants, governments are exploring policy options for providing new market incentives to drug developers.

Keywords: Antibacterials; Antibiotics; Antimicrobials; Antimicrobial resistance; Health economics; Pharmaceutical development; Pharmaceutical policy (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851020302980
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:125:y:2021:i:3:p:296-306

DOI: 10.1016/j.healthpol.2020.11.015

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().